This document discusses the transition to 2014 Edition meaningful use requirements and the hospital attestation process. It provides an overview of the changes from 2011 to 2014 editions, including increased thresholds and new objectives. It also outlines the steps for hospitals to obtain their CMS EHR certification ID number and attest through the registration system. Key areas like clinical quality measures and how they will be collected and reported using QRDA and value sets are reviewed.
This presentation will focus on the common types of deficiencies found by the TGA’s GMP Inspectors as well as some data on the number of inspections performed both locally and overseas and compliance rating outcomes for the inspections performed.
From the Nexus project showcase. Presented by Dr Martin Wilson, Clinical Leader I.T., Pegasus Health and Symon McHerron, CIO, Pegasus Health at HINZ 2014, 11 November 2014, 1.45pm, Plenary Room
This presentation correlates the requirements of Annex 11 guidelines to other official regulations and guidance documents.
The correlation is organized in a tabular format.
In the row lists the contents of Annex 11 together with the paragraph numbers.
Rest of the rows correlate the section numbers of
Annex 11 Versions 1993
US FDA 21 CFR Part 211
US FDA Part 820 and
US FDA 21 CFR Part 11
Data integrity is a Fundamental in a pharmaceutical quality system. It ensures that medicines are of required quality. This presentation is based on MHRA Guidance and provides MHRA expectations. Guidance complements existing EU GMP relating to active substances and dosage forms. This guidance should be d in conjunction with national medicines legislation and the GMP standards published in Eudralex volume 4.
This presentation describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products. It is a GMP requirement that manufacturer’s control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed.
This presentation will focus on the common types of deficiencies found by the TGA’s GMP Inspectors as well as some data on the number of inspections performed both locally and overseas and compliance rating outcomes for the inspections performed.
From the Nexus project showcase. Presented by Dr Martin Wilson, Clinical Leader I.T., Pegasus Health and Symon McHerron, CIO, Pegasus Health at HINZ 2014, 11 November 2014, 1.45pm, Plenary Room
This presentation correlates the requirements of Annex 11 guidelines to other official regulations and guidance documents.
The correlation is organized in a tabular format.
In the row lists the contents of Annex 11 together with the paragraph numbers.
Rest of the rows correlate the section numbers of
Annex 11 Versions 1993
US FDA 21 CFR Part 211
US FDA Part 820 and
US FDA 21 CFR Part 11
Data integrity is a Fundamental in a pharmaceutical quality system. It ensures that medicines are of required quality. This presentation is based on MHRA Guidance and provides MHRA expectations. Guidance complements existing EU GMP relating to active substances and dosage forms. This guidance should be d in conjunction with national medicines legislation and the GMP standards published in Eudralex volume 4.
This presentation describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products. It is a GMP requirement that manufacturer’s control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed.
:Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part F of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Production & Process Controls
The Quality Metrics Program is an FDA initiative aiming to collect data on certain manufacturing processes from biopharmaceutical companies through an electronic portal. In this presentation, we focus on the practicalities of the program.
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part D of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Equipment
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part H of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : : Laboratory Ccntrols
Scenario:
Midwest Regional Health is one of Wisconsin's largest and most sophisticated hospitals, is Implementing a new EHR system that will better their services to their internal and external customers. They are asking ITMC (I-Tech Medical Consortium) to help them navigate through this long term project, thereby improving their commitment to their surrounding community.
Provide recommendations and background information concerning computerised systems
Information will be of assistance to inspectors for training purposes and during the inspection
Where automated systems and electronic records are used in warehouses and similar establishments where GDP requirements are applicable, controls and disciplines outlined in this document, or a best practice alternatives are expected to be in place.
Vertically integrated companies (R&D, manufacturing and distribution) will already apply such controls and compliance measures.
International regulatory agencies have collaborated to produce this guidance.
Intended as a reference for regulated users, including their suppliers, in addition to regulatory inspectors and investigators.
Provides a logical explanation of the basic requirements for the implementation, validation and operation of computerised systems.
May be adapted to identify the criteria for a regulated user, or a regulatory agency, in an inspection of GxP computer systems.
National legislation should to be referred to when determining the extent to which the provisions laid down in this document may be applicable.
This presentation gives a summary of this guidance.
In today’s complex global supply chain, proper supplier qualification is essential for avoiding supply chain failures and maintaining traceability of products.
There have been numerous public health crises in various industries regulated by the US Food and Drug Administration (FDA) related to contamination or adulteration of material along the supply chain.
Under Food Safety modernization Act (FSMA) Food and Drug Administration (FDA) issued final rule for Foreign Supplier Verification Programs (FSVP) on November 13, 2015
United Health Care ICD-10 Testing Results November 2014Florida Blue
Shirley Reynolds, Senior Product Manager with United Health Group, shared testing results and lessons learned for ICD-10 on our November 21 Open Line Friday call. Be sure to visit www.floridablue.com/icd-10 for a comprehensive list of ICD-10 resources and archived content.
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part C of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Buildings & Facilities
WHO has recently issued draft document titled "Guidelines on Validation". These guidelines (i.e., the main text included in this working document) cover the general principles of validation and qualification.
These guidelines focus mainly on the overall concept of validation and are not intended to be prescriptive in specific validation requirements. This document serves as general guidance only and the principles may be considered useful in its application in the manufacture and control of starting materials and finished pharmaceutical products (FPPs), as well as other areas. Validation of specific processes and systems, for example, in sterile product manufacture, requires much more consideration and a detailed approach that is beyond the scope of this document. The general text in this document may be applicable to validation and qualification of premises, equipment, utilities, systems, processes, and procedures.
The draft on the specific topics, the appendices to this main text, will follow. The following is an overview on the appendices that are intended to complement the text of this working document:
Appendix 1: Validation of heating, ventilation and air-conditioning systems - will be replaced by cross reference to WHO Guidelines on GMP for HVAC systems for considerations in qualification of HVAC systems (update - working document QAS/15.639/Rev. 1)
Appendix 2: Validation of water systems for pharmaceutical use - will be replaced by cross-reference to WHO Guidelines on water for pharmaceutical use for consideration in qualification of water purification systems
Appendix 3: Cleaning validation - consensus to retain
Appendix 4: Analytical method validation - update in process
Appendix 5: Validation of computerized systems - update in process
Appendix 6: Qualification of systems and equipment - update in process
Appendix 7: Non-sterile process validation - update already published as Annex 3, WHO Technical Report Series, No. 992, 2015
Comments on this draft document are due by July 12, 2016.
A presentation on this guidance is given below:
Presentation on New WHO Guidance on Validations
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part A of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses Status , Scope & Definitions
:Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part F of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Production & Process Controls
The Quality Metrics Program is an FDA initiative aiming to collect data on certain manufacturing processes from biopharmaceutical companies through an electronic portal. In this presentation, we focus on the practicalities of the program.
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part D of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Equipment
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part H of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : : Laboratory Ccntrols
Scenario:
Midwest Regional Health is one of Wisconsin's largest and most sophisticated hospitals, is Implementing a new EHR system that will better their services to their internal and external customers. They are asking ITMC (I-Tech Medical Consortium) to help them navigate through this long term project, thereby improving their commitment to their surrounding community.
Provide recommendations and background information concerning computerised systems
Information will be of assistance to inspectors for training purposes and during the inspection
Where automated systems and electronic records are used in warehouses and similar establishments where GDP requirements are applicable, controls and disciplines outlined in this document, or a best practice alternatives are expected to be in place.
Vertically integrated companies (R&D, manufacturing and distribution) will already apply such controls and compliance measures.
International regulatory agencies have collaborated to produce this guidance.
Intended as a reference for regulated users, including their suppliers, in addition to regulatory inspectors and investigators.
Provides a logical explanation of the basic requirements for the implementation, validation and operation of computerised systems.
May be adapted to identify the criteria for a regulated user, or a regulatory agency, in an inspection of GxP computer systems.
National legislation should to be referred to when determining the extent to which the provisions laid down in this document may be applicable.
This presentation gives a summary of this guidance.
In today’s complex global supply chain, proper supplier qualification is essential for avoiding supply chain failures and maintaining traceability of products.
There have been numerous public health crises in various industries regulated by the US Food and Drug Administration (FDA) related to contamination or adulteration of material along the supply chain.
Under Food Safety modernization Act (FSMA) Food and Drug Administration (FDA) issued final rule for Foreign Supplier Verification Programs (FSVP) on November 13, 2015
United Health Care ICD-10 Testing Results November 2014Florida Blue
Shirley Reynolds, Senior Product Manager with United Health Group, shared testing results and lessons learned for ICD-10 on our November 21 Open Line Friday call. Be sure to visit www.floridablue.com/icd-10 for a comprehensive list of ICD-10 resources and archived content.
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part C of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses : Buildings & Facilities
WHO has recently issued draft document titled "Guidelines on Validation". These guidelines (i.e., the main text included in this working document) cover the general principles of validation and qualification.
These guidelines focus mainly on the overall concept of validation and are not intended to be prescriptive in specific validation requirements. This document serves as general guidance only and the principles may be considered useful in its application in the manufacture and control of starting materials and finished pharmaceutical products (FPPs), as well as other areas. Validation of specific processes and systems, for example, in sterile product manufacture, requires much more consideration and a detailed approach that is beyond the scope of this document. The general text in this document may be applicable to validation and qualification of premises, equipment, utilities, systems, processes, and procedures.
The draft on the specific topics, the appendices to this main text, will follow. The following is an overview on the appendices that are intended to complement the text of this working document:
Appendix 1: Validation of heating, ventilation and air-conditioning systems - will be replaced by cross reference to WHO Guidelines on GMP for HVAC systems for considerations in qualification of HVAC systems (update - working document QAS/15.639/Rev. 1)
Appendix 2: Validation of water systems for pharmaceutical use - will be replaced by cross-reference to WHO Guidelines on water for pharmaceutical use for consideration in qualification of water purification systems
Appendix 3: Cleaning validation - consensus to retain
Appendix 4: Analytical method validation - update in process
Appendix 5: Validation of computerized systems - update in process
Appendix 6: Qualification of systems and equipment - update in process
Appendix 7: Non-sterile process validation - update already published as Annex 3, WHO Technical Report Series, No. 992, 2015
Comments on this draft document are due by July 12, 2016.
A presentation on this guidance is given below:
Presentation on New WHO Guidance on Validations
Drug Regulations is a Not for Profit Organizations which provides free online resources for the Pharmaceutical Professional. This presentation is part A of series of presentations which addresses the current Good Manufacturing Requirements as per the US FDA. This presentation addresses Status , Scope & Definitions
Акция "Выгодный обмен. Check in в обмен на скидку"prasu1995
Проект для компании Билайн
Авторы: Качехина Бэлла (Связи с общественностью АлтГУ), Радько Екатерина (Связи с общественностью АлтГУ), Потапова Мария (ИнАрхДиз)
Выполнен в рамках "Мастерской рекламы", 2011
Adrian Hands Academy Parent Information SessionRhythm Sethi
Adrian Hands Academy (AHA) is tuition-free TK-8 public charter school (pending approval) with an emphasis in STEAM, Trilingual learning (Mandarin Chinese, Spanish, English) and Peacebuilding. We will be located in South Orange County within Saddleback Valley Unified School District.
To learn more, contact us at info@adrianhandsacademy.org
Проект для компании Билайн
Авторы: Авдеева Оксана (Связи с общественностью АлтГУ), Цыклакова Яна (ИнАрхДиз)
Выполнен в рамках "Мастерской рекламы", 2011
Go deeper with athenahealth specialists to discover all that you need to know and some things you may not know about Meaningful Use Stage 2 and the newest government updates.
This presentation walks through the transition from chart abstracted quality reporting to electronic quality reporting for the CMS and The Joint Commission
The Alphabet Soup of Clinical Quality Measures ReportingBill Presley
CMS is transitioning to what the they call "a new and more responsive regulatory framework" for quality reporting and reimbursement. CMS goals are "…electronic health records helping physicians, clinicians, and hospitals to deliver better care, smarter spending, and healthier people". Over the next couple years, we will see a transformation of fee for service into value-based care models driven by the VBP, Quality Payment Program, MACRA, Merit-based Incentive Payment System (MIPS) and Alternative Payment Models (APM). Healthcare organizations will no longer be motivated by implementing and meeting Meaningful Use, but instead will be driven by value-based care and risk-based payment models that focus on quality outcomes for reimbursements.
In this Education Session we will review:
• How CMS is aligning clinical quality measures (CQMs) to reduce the reporting burden for healthcare organizations and providers. We will cover the vision and goals for achieving quality alignment for CMS.
• We will dive into the following CMS reporting programs and how they interact with each other: Value-Based Purchasing (VBP), Medicare Access and CHIP Reauthorization Act (MACRA), Merit-based Incentive Payments (MIPS), Hospital Inpatient Quality Reporting (IQR), The Joint Commission (ORYX), Outpatient Quality Reporting (OQR), and Alternative Payment Models (APM).
Healthcare IT product development involves a lot of Compliance and Security related component development which can be accomplished in various ways. Harbinger has been working on Meaningful Use Stage 2 related software development in HIT products and has gathered useful insights into Secure Patient Health Information exchange, Patient Health Record privacy and security along with simplification of MU Stage 2 attestation & testing through automation.
Attendees got insight on the prerequisites and the technological approach required with examples in accomplishing attestation to meaningful use stage 2 for Healthcare IT systems in a structured manner.
Keynote Presentation "Meaningful Use Stage 2 and Meaningful Use Audit Insight"
Think far beyond just threshold increases. The differences between Meaningful Use (MU) Stage 1 and Stage 2, including the 2014 Clinical Quality Measures, are technically and clinically challenging. And just when you thought you could safely look at Stage 1 in the rearview mirror, here come the audits! I will highlight the Stage 1 and Stage 2 differences and talk about the challenges they have initiated at Tenet. I will touch on the impact of Quality measures and will also provide you with insight into the basics of MU Audits and will take you through the actual audit experience at Tenet.
Learning Objectives:
∙ Review the program and measure changes from Stage 1 to Stage 2 and how the changes are being managed at Tenet
∙ Provide insight into the 2014 Clinical Quality Measures chosen by Tenet, the challenges posed, solutions that work and a little about the overall
impact of Quality measures
∙ Discuss Meaningful Use Audits, covering the basics as well as providing the benefit of the Tenet experience
The Medicare and Medicaid EHR Incentive Programs offer financial incentives for the
“meaningful use” of certified EHR technology to improve patient care. Read More.. www.curemd.com
ASCVD EHR Integration Pilot Using FHIRDino Damalas
Copy of Dr. Gluckman's presentation during HIMSS 16 that discusses the value of the ASCVD Risk Estimator and pilots being conducted by the American College of Cardiology to integrate the tool with EHRs using FHIR.
Stage 2 Meaningful Use brings more stringent requirements for the Stage 1 measures, a host of new measures, and a greater focus on clinical quality measures. In this instructive session, our expert faculty members review:
*The requirements and timeline for implementation of Stage 2 Meaningful Use
*The top five questions you need to ask to determine if your organization is ready for Stage 2
*The steps you can take to prepare your organization to successfully meet the Stage 2 requirements and get the most out of your EHR system
As providers face increasing regulation, it is critical to understand the driving forces behind these laws, the barriers to adoption, and the practical ways these new rules can be turned into opportunities. Learn the history and importance of recent legislation (including ARRA and HITECH), the purpose and practical implications of Meaningful Use, an overview of requirements for Meaningful Use Stage 1 and updates on Stage 2.
PYA Highlights Next Steps of Meaningful UsePYA, P.C.
At the 2013 AICPA Healthcare Industry Conference, PYA Principal David McMillan and Senior Manager Chris Wilson recently explored the “new normal” of meaningful use as compliance and strategic standards in new care/reimbursement-model development.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Telehealth Psychology Building Trust with Clients.pptx
Preparing for meaningful use stage 2
1. By Bill Presley
September 27, 2013
Transforming Data to Knowledge…
Preparing for Meaningful Use Stage 2
2.
3. Significant Accomplishment for
Acmeware
Total Certified EHR Vendors
2011
Edition
2014
Edition
http://www.ihealthbeat.org/articles/2013/9/26/fewer-stage-2-certified-ehr-systems-could-pose-problems
4. OneView 2014 Edition Transition
Customer wants to know what the
transition will be for the 2014 Edition?
OneView will need to be upgraded to 4.0 2014
Edition including changes for Core, Menu set and
Clinical Quality measures. We are developing a
2014 Edition implementation project plan which
will be available in October.
5. Agenda
Attestation Process for a Hospital
Attestation Process in OneView
Meaningful Use 2014 Edition
Stage 1 and Stage 2
6. Hospital Attestation Process
A successful and active Registration in the
CMS website. https://ehrincentives.cms.gov
Completed the appropriate reporting period
and met measures
Obtain EHR Certification Identification
Number
Attest online!
7. Registration and Attestation
System
• Registration User Guide
• Step-by-Step guide for EH's.
https://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/dow
nloads/EHRHospital_RegistrationUserGuide.pdf
8. Registration and Attestation
System
• Attestation User Guide
• Step-by-Step guide for EH's.
https://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/do
wnloads/HospAttestationUserGuide.pdf
9. Registration and Attestation
System
• Timelines
http://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/Downl
oads/HIT-Programs-Timeline-2012-.pdf
10. EHR Certification Identification
Number
CMS EHR Certification Identification
Number is a number generated by the
Certified Health IT Product List (CHPL)
used for reporting to CMS for
Meaningful Use attestation.
It represents a product or combination
of products in the CHPL.
12. EHR Certification Identification
Number (Cont.)
Each Hospital must obtain their your own
unique CMS HER Certification ID from the
Certified Health IT Product List website
cart.
13. Steps to obtaining CMS EHR
Certification ID Number
• Visit Certified Health IT Product List website
at http://oncchpl.force.com/ehrcert.
• Select which edition of ONC HIT EHR
Certification are you attesting?
• Select the practice type by selecting the
Ambulatory or Inpatient buttons.
14. Steps to obtaining CMS EHR
Certification ID Number (Cont.)
• Search for the Certified EHR Products being used.
There is the option of browsing all products,
searching by product name, number, vendor, or
searching by criteria met.
15. Steps to obtaining CMS EHR
Certification ID Number (Cont.)
• Add product(s) to the cart to determine if your
product(s) meet 100% of the required criteria.
16. Steps to obtaining CMS EHR
Certification ID Number (Cont.)
• Request a CMS EHR Certification ID for CMS
registration or attestation from your cart page
17. Attestation Process with OneView
SQL Server Agent Job Disabled
Hospital Settings Updated
Attestation Locked
Alerts & Subscription Disabled
Audit Preparation with Supporting
Documentation
18. SQL Server Agent Job Disabled
Disable job once Medical Records
has completed coding and
abstracting for the reporting period
and hospital is ready to attest.
20. Attestation Locked
Start an Attestation under the
Attestation section
Select appropriate reporting period
Everything should have green
checks
Lock it when hospital is ready to
attest
23. Audit Preparation with Supporting
Documentation
Relevant supporting documentation
associated with a CQM, CM, or MSM
Measure
MEDITECH screenshots
Payment calculations
ONC EHR licensing documentation
OneView Invoices
24. Meaningful Use 2014 Edition -
Stage 1 and Stage 2
Other Resources
Glen’s MUSE International 2013 a presentation EHR
Meaningful Use 2014 (Stage 2)
http://www.acmeware.com/downloads/EH
R%20Meaningful%20Use%202014%20(St
age%202)%20DR%20Reporting%20Strate
gies.pdf
25. Meaningful Use 2014 Edition -
Stage 1 and Stage 2
EP, EH, CAH - What do they mean?
EP - Eligible Provider
Ambulatory/Clinic Typically Office Visit
Using Systems like AthenaHealth, eClinicalWorks,
LSS
EH/CAH - Eligible Hospital/Critical Access Hospital
Inpatient and ED depending on method
2 Methods for ED
Observation Services method
All ED Visits method
https://questions.cms.gov/faq.php?id=5005&faqId=2843
http://www.cms.gov/Outreach-and-Education/Medicare-Learning-
Network-MLN/MLNProducts/downloads/critaccesshospfctsht.pdf
26. Stages of Meaningful Use
Editions not Stages
Do not confuse 2014 Edition with
Stage 2
http://www.healthit.gov/policy-researchers-implementers/meaningful-
use-stage-2
30. 2014 Edition Stage 1 & Stage 2
All EH/CAH’s need to upgrade to 2014 Edition
certified EHR technology in 2014
Regardless of the meaningful use stage
Requirements that update the baselines for
interoperability, health information
exchange (HIE), and patient engagement.
IMPORTANT!
2011 Edition will no longer be acceptable as
"Certified EHR Technology” and regulatory
officials perspective 2011 Edition certifications
will expire the start of 2014 MU reporting period.
31. 2014 Edition Stage 1 & Stage 2
2014 Meaningful Use reporting period
If first year was 2013 Stage 1 90 days, then 2014 will be
Stage 1 90 days.
The 2014 MU reporting period for both Stage 1 and
Stage 2 is set to one calendar quarter during a
Medicare EH/CAH reporting year.
(e.g., April 1, 2014 through June 30, 2014 would be a
Medicare EH/CAH 3rd quarter)
32. 2014 Edition Stage 1
Meaningful Use 2014 Edition starts a
beginning of a reorganized Stage 1
• Some Core and Menu removed/combined
• No Longer Count Measure Exclusions
• Stage 1 Thresholds Increases
• View, Download, Transmit to 3rd Party
more then 50% of unique patients
33. 2014 Edition Stage 1
Changes between 2011 Stage 1 and 2013
Stage 1
Stage 1 Changes Tip sheet
http://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/Downloads
/Stage1ChangesTipsheet.pdf
34. 2014 Edition Stage 2
• New Objectives & Measures
• Core Measures
• eMAR
• View Online, Download and Transmit
• Menu Set Measures
• Record electronic notes in patient records
• Imaging results accessible
• Record patient family health history
• Generate and transmit permissible discharge
prescriptions electronically (eRx)
• Provide structured electronic lab results to ambulatory
providers
35. 2014 Edition Stage 2
Clinical Quality Measures for 2014
Select CQMs from 3 of these 6 domain
16 out of 29 total CQMs
CQM's must be submitted electronically to CMS
HL7 QRDA (Quality Reporting Document
Architecture) has been approved as a
standard for clinical data exchange for
Quality Measures
CMS approved standardized Nomenclature
36. Clinical Quality Measures for 2014
• Introduction of universal identifier, eMeasure ID
NQF# (VTE-1 = 0371)
• How will standardized nomenclature based code
system work?
• Using Quality Data Model (QDM) with HL7 QRDA
(Quality Reporting Document Architecture)
37. Venous Thromboembolism
Prophylaxis NQF#: 0371
Description:
This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE
prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day
of or the day after hospital admission.
Data criteria (QDM Data Elements):
"Medication, Administered: Warfarin" using "Warfarin RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.232)“
"Medication, Administered: Direct Thrombin Inhibitor" using "Direct Thrombin Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.205)"
"Medication, Administered: Injectable Factor Xa Inhibitor" using "Injectable Factor Xa Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.211)"
"Medication, Administered: Low Molecular Weight Heparin" using "Low Molecular Weight Heparin RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.219)"
"Medication, Administered: Oral Factor Xa Inhibitor" using "Oral Factor Xa Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.134)"
"Medication, Administered: Unfractionated Heparin" using "Unfractionated Heparin RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.218)"
38. Venous Thromboembolism
Prophylaxis - NQF#: 0371
Data criteria (QDM Data Elements):
"Medication, Administered: Warfarin" using "Warfarin RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.232)“
Value Set Table:
39. Venous Thromboembolism
Prophylaxis - NQF#: 0371
Data criteria (QDM Data Elements):
"Medication, Administered: Warfarin" using "Warfarin RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.232)“
"Medication, Administered: Direct Thrombin Inhibitor" using "Direct Thrombin Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.205)"
"Medication, Administered: Injectable Factor Xa Inhibitor" using "Injectable Factor Xa Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.211)"
"Medication, Administered: Low Molecular Weight Heparin" using "Low Molecular Weight Heparin RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.219)"
"Medication, Administered: Oral Factor Xa Inhibitor" using "Oral Factor Xa Inhibitor RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.134)"
"Medication, Administered: Unfractionated Heparin" using "Unfractionated Heparin RxNorm Value Set
(2.16.840.1.113883.3.117.1.7.1.218)"
40. Venous Thromboembolism
Prophylaxis - NQF#: 0371
Data criteria (QDM Data Elements):
"Medication, Administered: Warfarin" using "Warfarin RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.232)“
Value Set Table:
This shows a value set for a class of medications (Warfarin)
43. Meaningful Use 2014 Edition
Why does 2014 Edition matter?
Don't get caught up in the incentive payments
• 2014 MU determines Medicare payment
adjustments.
http://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/Downloads/PaymentAdj_HardshipExcepTipsheetforHospitals.pdf